Ferrey G, Sicot C
Encephale. 1985 Jul-Aug;11(4):135-44.
The goal of this article is to inform psychiatrists of the hepatotoxicity of certain drugs used for the treatment of psychiatric disorders. A review of biochemical pathways lends support to the argument that toxicity is due to certain toxic metabolites. The physiopathology of these disorders, which are rare, requires an appreciation of an individual's biochemical make up which can explain the quantity of active metabolites produced, the occurrence of immunological reactions and the contributing factor of enzymatic induction resulting from the simultaneous prescription of several medications. The most serious disorder is cytotoxic hepatitis which has a 10 to 20 per cent mortality. The molecules which may cause this affection in less than one out of a thousand cases are the hydrazide M.A.O. inhibitors and valproic acid. These medications should not be prescribed without being aware of their drawbacks and after a failure to achieve improvement with other drugs having a similar action. Obviously it is important to prescribe no more than moderate doses, and to avoid prescribing medications which, together can occasion enzymatic induction. The most common complication is obstructive jaundice for which the clinical and biological diagnosis should be made early in the course of the disorder. The medication should be stopped immediately and further prescription, in patients who have already presented this disorder, when a molecule is known to have certain toxic side effects (phenothiazines and tricyclics), suspended this surveillance should be carried out over a three months period. The occurrence of jaundice during a period of treatment is not always iatrogenic. It is always necessary to ascertain the etiology by asking a specialist to do a complete workup.
本文的目的是告知精神科医生用于治疗精神障碍的某些药物的肝毒性。对生化途径的回顾支持了毒性是由某些有毒代谢物引起的这一观点。这些罕见疾病的生理病理学需要了解个体的生化构成,这可以解释活性代谢物的产生量、免疫反应的发生以及几种药物同时处方导致的酶诱导的促成因素。最严重的疾病是细胞毒性肝炎,其死亡率为10%至20%。在不到千分之一的病例中可能导致这种情况的分子是肼类单胺氧化酶抑制剂和丙戊酸。在不了解其缺点且使用其他具有类似作用的药物未能取得改善之前,不应开具这些药物。显然,重要的是开具不超过适度剂量的药物,并避免开具可能共同引起酶诱导的药物。最常见的并发症是阻塞性黄疸,对此应在疾病过程中尽早进行临床和生物学诊断。如果已知某种分子有某些毒性副作用(吩噻嗪类和三环类药物),对于已经出现这种疾病的患者,应立即停药并暂停进一步处方,应在三个月期间进行监测。治疗期间黄疸的出现并不总是医源性的。总是有必要请专家进行全面检查以确定病因。